CCLA Investment Management Ltd Has $76.33 Million Holdings in Zoetis Inc. (NYSE:ZTS)

CCLA Investment Management Ltd lessened its stake in shares of Zoetis Inc. (NYSE:ZTSGet Rating) by 1.5% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 404,503 shares of the company’s stock after selling 6,160 shares during the quarter. CCLA Investment Management Ltd’s holdings in Zoetis were worth $76,329,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in ZTS. Norges Bank acquired a new position in shares of Zoetis in the 4th quarter valued at about $1,067,881,000. Castleview Partners LLC acquired a new position in Zoetis in the fourth quarter worth approximately $6,000,000. BlackRock Inc. increased its holdings in Zoetis by 3.7% in the fourth quarter. BlackRock Inc. now owns 40,315,810 shares of the company’s stock worth $9,838,266,000 after buying an additional 1,427,812 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in Zoetis in the fourth quarter worth approximately $196,317,000. Finally, Marshall Wace LLP increased its holdings in Zoetis by 90.1% in the fourth quarter. Marshall Wace LLP now owns 1,142,793 shares of the company’s stock worth $278,876,000 after buying an additional 541,656 shares during the last quarter. Institutional investors and hedge funds own 90.73% of the company’s stock.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 4,334 shares of the stock in a transaction on Monday, June 27th. The stock was sold at an average price of $175.00, for a total transaction of $758,450.00. Following the completion of the transaction, the executive vice president now directly owns 23,687 shares in the company, valued at $4,145,225. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Zoetis news, Director Willie M. Reed sold 1,855 shares of the stock in a transaction on Friday, June 10th. The stock was sold at an average price of $162.31, for a total transaction of $301,085.05. Following the completion of the transaction, the director now directly owns 6,782 shares in the company, valued at $1,100,786.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Roxanne Lagano sold 4,334 shares of the firm’s stock in a transaction on Monday, June 27th. The shares were sold at an average price of $175.00, for a total value of $758,450.00. Following the completion of the sale, the executive vice president now owns 23,687 shares of the company’s stock, valued at $4,145,225. The disclosure for this sale can be found here. Insiders sold 18,356 shares of company stock worth $3,250,158 over the last three months. 0.12% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on ZTS shares. StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 26th. The Goldman Sachs Group decreased their target price on Zoetis from $208.00 to $202.00 and set a “buy” rating for the company in a research report on Thursday, July 21st. Stifel Nicolaus decreased their target price on Zoetis from $275.00 to $225.00 and set a “buy” rating for the company in a research report on Friday, June 24th. Finally, Piper Sandler initiated coverage on Zoetis in a research report on Monday, July 11th. They set an “overweight” rating and a $205.00 target price for the company. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, Zoetis has an average rating of “Moderate Buy” and a consensus price target of $224.88.

Zoetis Stock Up 0.6 %

ZTS opened at $177.47 on Thursday. Zoetis Inc. has a 1-year low of $154.18 and a 1-year high of $249.27. The company has a current ratio of 2.25, a quick ratio of 1.58 and a debt-to-equity ratio of 1.12. The stock has a market capitalization of $83.52 billion, a price-to-earnings ratio of 40.70, a P/E/G ratio of 2.94 and a beta of 0.73. The business has a 50 day moving average of $169.72 and a 200-day moving average of $182.79.

Zoetis (NYSE:ZTSGet Rating) last issued its earnings results on Thursday, May 5th. The company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.22 by $0.10. The firm had revenue of $2 billion during the quarter, compared to analysts’ expectations of $1.98 billion. Zoetis had a return on equity of 49.62% and a net margin of 26.27%. Zoetis’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same period last year, the business earned $1.26 earnings per share. As a group, sell-side analysts anticipate that Zoetis Inc. will post 5.05 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 1st. Shareholders of record on Thursday, July 21st will be paid a dividend of $0.325 per share. The ex-dividend date of this dividend is Wednesday, July 20th. This represents a $1.30 annualized dividend and a yield of 0.73%. Zoetis’s dividend payout ratio is currently 29.82%.

About Zoetis

(Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Articles

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSGet Rating).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.